Towards vaccine optimisation.
New molecular technologies have accelerated the search for sub-unit candidate vaccines. However, once identified the use of a candidate antigen must be optimised to reap the maximum benefit from the eventual vaccine. This optimisation should take into account both the needs of the target population, and the various ways of potentiating the protective immune response induced. One must be sure that the final product will be used. Hence, vaccine optimisation should strive toward meeting the needs of a specific epidemiological problem within the economic constraints of a given situation. This may be possible using novel delivery systems designed to limit the number of doses needed, improve the stability or facilitate the delivery of a particular vaccine. In meeting the needs of a target population in a field situation, one must also keep in mind certain safety factors that go beyond the usual regulatory constraints. The immune response to vaccine candidates can be potentiated in many ways. The ability to preferentially induce specific protective effector mechanisms: i.e., antibody isotypes, T-cell subsets, and T-cell sub-subsets, is becoming a reality. Carrier molecules designed to avoid the problems of epitope suppression and competition, and perhaps an eventual "carrier jam," are being developed. Adjuvants and immunostimulants may also help, but the critical issue here remains their acceptability for use in man. Finally novel strategies for the induction of the immune response may also potentiate the immune response in the optimisation of vaccines.
Lussow
A R
AR
World Health Organisation-Immunology Research and Training Centre, Dept. of Pathology, University of Geneva, Switzerland.
Aguado
M T
MT
Del Giudice
G
G
Lambert
P H
PH
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D006801:Humans; D008288:Malaria / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic
D000276:Adjuvants, Immunologic; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic